Results
EORTC hosts first SPECTAforum, Screening Program for Efficient Clinical Trial Access, in Brussels
14 Nov 2013
Post
The first European multi-stakeholder model to address biomarker based drug development and promote innovative partnership successfully gathered in Brussels on 07 November 2013. The meeting convened circa 80 selected representatives of patient groups, academic researchers, regulators, government, European Union commission, pharmaceutical industry sector, and diagnostic and technology companies alongside EORTC officers and representatives.
EORTC putting together SPECTAlung for patients with lung cancer
14 Nov 2013
Post
The EORTC has announced that it will build a Screening Program for Efficient Clinical Trial Access for patients with lung cancer. This program, SPECTAlung, will prospectively collect biological materials from patients who have been diagnosed with lung cancer, starting with non-small cell lung cancer (NSCLC) and enable efficient clinical trial access for these patients.
EGAM 2013: Videos of the presentations are available for viewing
14 Mar 2013
Post
Thursday 7 March 2013
Opening remarks & Positioning the EORTC in the changing clinical research landscape - R. Stupp
New EORTC studies activated in 2012
3 Jan 2013
Post
EORTC trial 18081
Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group
Target Accrual: 1200 patients
Study Coordinator:
Alessandro Testori - Istituto Europeo Di Oncologia, Milano